Regular Article
Differential Effects of Trivalent and Pentavalent Arsenicals on Cell Proliferation and Cytokine Secretion in Normal Human Epidermal Keratinocytes

https://doi.org/10.1006/taap.2001.9152Get rights and content

Abstract

There is strong evidence from epidemiologic studies of an association between chronic exposure to inorganic arsenic (iAs) and hyperpigmentation, hyperkeratosis, and neoplasia in the skin. Although it is generally accepted that methylation is a mechanism of arsenic detoxification, recent studies have suggested that methylated arsenicals also have deleterious biological effects. In these studies we compare the effects of inorganic arsenicals (arsenite (iAsIII) and arsenate (iAsV)) and trivalent and pentavalent methylated arsenicals (methylarsine oxide (MAsIIIO), complex of dimethylarsinous acid with glutathione (DMAsIIIGS), methylarsonic acid (MAsV), and dimethylarsinic acid (DMAsV)) in human keratinocyte cultures. Viability testing showed that the relative toxicities of the arsenicals were as follows: iAsIII > MAsIIIO > DMAsIIIGS > DMAsV > MAsV > iAsV. Trivalent arsenicals induced an increase in cell proliferation at concentrations in the 0.001 to 0.01 μM range, while at high concentrations (>0.5 μM) cell proliferation was inhibited. Pentavalent arsenicals did not stimulate cell proliferation. As seen in the viability studies, the methylated forms of AsV were more cytotoxic than iAsV. Exposure to low doses of trivalent arsenicals stimulated secretion of the growth-promoting cytokines, granulocyte macrophage colony stimulating factor and tumor necrosis factor-α. DMAsV reduced cytokine secretion at concentrations at which proliferation and viability were not affected. These data suggest that methylated arsenicals, products of the metabolic conversion of inorganic arsenic, can significantly affect viability and proliferation of human keratinocytes and modify their secretion of inflammatory and growth-promoting cytokines.

References (67)

  • D.R. Germolec et al.

    Arsenic can mediate skin neoplasia by chronic stimulation of keratinocyte-derived growth factors

    Mutat. Res.

    (1997)
  • D.R. Germolec et al.

    Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors

    Am. J. Pathol.

    (1998)
  • H.K. Hamadeh et al.

    Arsenic disrupts cellular levels of p53 and mdm2: A potential mechanism of carcinogenesis

    Biochem. Biophys. Res. Commun.

    (1999)
  • Y. Hashimoto et al.

    Flow cytometric analysis of pig epidermal keratinocytes: Effects of ultraviolet B irradiation (UVB) and topical PUVA treatment

    J. Dermatol. Sci.

    (1995)
  • S.M. Healy et al.

    Enzymatic methylation of arsenic compounds. V. Arsenite methyltransferase activity in tissues of mice

    Toxicol. Appl. Pharmacol.

    (1998)
  • R.-N. Huang et al.

    Cellular uptake of trivalent arsenite and pentavalent arsenate in KB cells cultured in phosphate-free medium

    Toxicol. Appl. Pharmacol.

    (1996)
  • D.J. Kachinskas et al.

    Arsenate suppression of human keratinocyte programming

    Mutat. Res.

    (1997)
  • S.A. Lerman et al.

    Arsenic uptake and metabolism by liver cells is dependent on arsenic oxidation state

    Chem.–Biol. Interact.

    (1983)
  • W. Li et al.

    Promotion of NCI-Black-Reiter male rat bladder carcinogenesis by dimethylarsinic acid an organic arsenic compound

    Cancer Lett.

    (1998)
  • H. Matsue et al.

    Reciprocal cytokine-mediated cellular interactions in mouse epidermis: Promotion of gd T-cell growth by IL-7 and TNFα and inhibition of keratinocyte growth by gIFN

    J. Invest. Dermatol.

    (1993)
  • M.M. Moore et al.

    Relative genotoxic potency of arsenic and its methylated metabolites

    Mutat. Res.

    (1997)
  • N. Oyama et al.

    Induction of transcription factor AP-2 by inflammatory cytokines in human keratinocytes

    J. Invest. Dermatol.

    (1999)
  • M. Partridge et al.

    Production of interleukin-1 and interleukin-6 by human keratinocytes and squamous cell carcinoma cell lines

    J. Invest. Dermatol.

    (1991)
  • J.S. Petrick et al.

    Monomethylarsonous acid (MMAIII) is more toxic than arsenite in Chang human hepatocytes

    Toxicol. Appl. Pharmacol.

    (2000)
  • P.F. Reay et al.

    Preparation and purification of 74As-labeled arsenate and arsenite for use in biological experiments

    Anal. Biochem.

    (1977)
  • T.G. Rossman et al.

    Human cells lack the inducible tolerance to arsenite seen in hamster cells

    Mutat. Res.

    (1997)
  • M. Styblo et al.

    Comparative methylation of trivalent and pentavalent arsenicals

    Toxicol. Appl. Pharmacol.

    (1995)
  • M. Styblo et al.

    Liberation and analysis of protein-bound arsenicals

    J. Chromatgr. B

    (1996)
  • M. Styblo et al.

    Binding of arsenicals to proteins in an in vitro methylation system

    Toxicol. Appl. Pharmacol.

    (1997)
  • M. Styblo et al.

    Metabolism and toxicity of arsenicals in cultured cells

  • M. Vahter

    Biotransformation of trivalent and pentavalent inorganic arsenic in mice and rats

    Environ. Res.

    (1981)
  • J. Ansel et al.

    Cytokine modulation of keratinocyte cytokines

    J. Invest. Dermatol.

    (1990)
  • H.V. Aposhian

    Enzymatic methylation of arsenic species and other new approaches to arsenic toxicity

    Annu. Rev. Pharmacol. Toxicol.

    (1997)
  • Cited by (258)

    • Arsenic

      2023, Inorganic Contaminants and Radionuclides
    View all citing articles on Scopus
    1

    To whom correspondence should be addressed at 111 T.W. Alexander Drive, Bldg. 101, MD C1-04, P.O. Box 12233, Research Triangle Park, NC 27709. Fax: (919) 541-0870; E-mail: [email protected].

    View full text